MedPath

University of Alberta

University of Alberta logo
🇨🇦Canada
Ownership
Private
Established
1908-01-01
Employees
10K
Market Cap
-
Website
http://www.ualberta.ca

Clinical Trials

773

Active:27
Completed:448

Trial Phases

6 Phases

Early Phase 1:5
Phase 1:55
Phase 2:100
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (659 trials with phase data)• Click on a phase to view related trials

Not Applicable
416 (63.1%)
Phase 2
100 (15.2%)
Phase 1
55 (8.3%)
Phase 4
50 (7.6%)
Phase 3
33 (5.0%)
Early Phase 1
5 (0.8%)

Adipose Tissues and Liver Changes Associated Semaglutide in CKD

Not yet recruiting
Conditions
Chronic Kidney Disease in Type 2 Diabetes
Interventions
First Posted Date
2025-09-23
Last Posted Date
2025-09-23
Lead Sponsor
University of Alberta
Target Recruit Count
62
Registration Number
NCT07187830
Locations
🇨🇦

Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada

Connecting Today to Combat Social Isolation and Loneliness

Not Applicable
Not yet recruiting
Conditions
Dementia in Nursing Home
Family
Remote Visits
First Posted Date
2025-09-19
Last Posted Date
2025-09-23
Lead Sponsor
University of Alberta
Target Recruit Count
320
Registration Number
NCT07182019

Sotatercept in Pulmonary Arterial Hypertension

Not Applicable
Not yet recruiting
Conditions
Pulmonary Artery Hypertension
Interventions
First Posted Date
2025-08-24
Last Posted Date
2025-08-24
Lead Sponsor
University of Alberta
Target Recruit Count
27
Registration Number
NCT07140484

A Game-based Screening for MCI Detection in Older Adults

Completed
Conditions
Mild Cognitive Impairment (MCI)
First Posted Date
2025-08-22
Last Posted Date
2025-08-22
Lead Sponsor
University of Alberta
Target Recruit Count
59
Registration Number
NCT07137650
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

Language Translation of Knowledge Mobilization Resources

Not Applicable
Recruiting
Conditions
Communication Research
First Posted Date
2025-08-17
Last Posted Date
2025-08-17
Lead Sponsor
University of Alberta
Target Recruit Count
350
Registration Number
NCT07127887
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 155
  • Next

News

Onco-Innovations Partners with University of Alberta to Advance PNKP Inhibitor Research for Glioblastoma Treatment

Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme.

World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival

A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.

Onco-Innovations Initiates Manufacturing of PNKP Inhibitor for Preclinical Testing

Onco-Innovations has partnered with Dalton Pharma Services to begin manufacturing 50 grams of their proprietary PNKP inhibitor A83B4C63 for preclinical testing.

University of Alberta's Novel Cancer Drug Zelenirstat Receives FDA Fast-Track Designation

University of Alberta researchers have developed Zelenirstat, an innovative oral cancer medication that works by preventing cancer cell spread and starving tumors.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.